Studies โบ Follow-up ยท Last reviewed 2026-05-16
Follow-up studies overview
Summary
Long-term data on the Dutch Protocol remain limited. This page collects published cohort and outcome studies, with sample size, follow-up duration, attrition and main findings. The NICE reviews (2020) rated all results as very low certainty (source). The University of York systematic review for the Cass Review (2024) concluded that no conclusions can be drawn about the effect of puberty blockers on gender dysphoria and mental health (source), and the Swedish SBU (2022) found the evidence on hormone treatment insufficient to assess its effects (source).
Overview (selection)
| Study | n | Follow-up | Main finding |
|---|---|---|---|
| de Vries 2011 | 70 | Until start of hormones (T1) | Behavioural and emotional problems and depressive symptoms decreased and general functioning improved; gender dysphoria and body satisfaction did not change (source) |
| de Vries 2014 | 55 | โฅ 1 yr post-op | Gender dysphoria alleviated; well-being similar to or better than same-age young adults from the general population (source) |
| Costa et al. 2015 | 201 (UK, GIDS) | Measured every 6 months | Global functioning (CGAS) improved after 6 months of psychological support; after 12 months of GnRHa it was higher than when only support was given (source) |
| Carmichael 2021 | 44 (UK, GIDS early intervention) | 12, 24 and 36 months (44, 24 and 14 participants) | No changes in psychological function (source) |
| Brik et al. 2020 | 143 | median 0.8 yrs on GnRHa | 87% started hormones; 6% (9 adolescents) discontinued GnRHa (source) |
| van der Loos 2022 | 720 | until end of 2018 | 98% (704) were still using hormones at the end of data collection (source) |
| van der Loos 2023 | 1,766 | retrospective cohort, 20 years | 1.4% stopped GnRHa, mostly because gender dysphoria remitted (source) |
Common limitations
- No RCTs in this clinical domain.
- Heterogeneous outcome measures โ comparison between studies hindered.
- Long-term data (10+ years) largely missing.
Conclusion of systematic reviews
SBU (2022) found the evidence on hormone treatment of children with gender dysphoria insufficient to assess its effects (source). The University of York review for the Cass Review (2024) found that of 50 studies on puberty suppression 1 was of high, 25 of moderate and 24 of low quality, and concluded that no conclusions can be drawn about the effect on gender dysphoria and mental health (source).1
Critical note
Most adolescents on puberty blockers went on to hormones: 98% (43 of 44) in the UK early intervention study and 98% and 93% in two Dutch studies (source). Brik et al. describe the GnRHa phase as an "extended diagnostic phase", but also write that the vast majority proceeded to hormones, possibly because the eligibility criteria select those likely to proceed, and that because of the observational design it cannot be said whether the treatment itself influenced the outcome (source). The Cass Review writes that there is no evidence that puberty blockers buy time to think (source). A Finnish register study (Ruuska et al., 2026) found that among adolescents who underwent medical gender reassignment, severe psychiatric morbidity rose during follow-up (from 9.8% to 60.7% for feminising and from 21.6% to 54.5% for masculinising treatment); the authors also report that, after adjusting for prior psychiatric treatment, all gender-referred adolescents had similarly elevated risks (source).2
See also
- Individual study summaries: de Vries 2011, de Vries 2014, Costa/Carmichael (replication)
- Attrition analysis: Sample size and attrition
- Methodological criticism: Methodological criticism, Biggs
- Systematic evaluation: Cass Review, SBU
- Clinical aftercare structure: Follow-up in the Dutch Protocol
- People register โ de Vries, van der Loos, Costa, Carmichael.
- Timeline โ follow-up publications in chronology.
- Original publications โ full bibliography.
- FAQ ยท Glossary.
Footnotes
- Taylor J, Mitchell A, Hall R, et al. Interventions to suppress puberty in adolescents experiencing gender dysphoria. Arch Dis Child. 2024; University of York / Cass Review systematic review.
- Brik T, Vrouenraets LJJJ, de Vries MC, Hannema SE. Trajectories of adolescents treated with gonadotropin-releasing hormone analogues for gender dysphoria. Arch Sex Behav. 2020;49:2611โ2618.